Camurus announces that the US Food and Drug Administration has approved Brixadi™ extended release injection for subcutaneous use, a weekly and monthly medication for the treatment of moderate to severe opioid use disorder, in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a daily buprenorphine product.
